Oxalic Acid

Oxalic Acid

SCHEMBL3543097

FC(F)(F)c1ccc(C2CCNC2)cc1.O=C(O)C(=O)O

nearest known ligand 0.73

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

OPRM1SLC6A4

The experimentally established mechanism targets of Oxalic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A4 known ✓ P31645 1/20 0.49
HTR2C P28335 2/20 0.66
P2RY14 Q15391 3/20 0.58
TMEM97 Q5BJF2 2/20 0.58
JAK3 P52333 1/20 0.52
HTR3A P46098 1/20 0.50
PDE2A O00408 1/20 0.49
PDE5A O76074 1/20 0.49
EGFR P00533 1/20 0.49
INSR P06213 1/20 0.49
HTR1A P08908 1/20 0.49
ADRA2A P08913 1/20 0.49
ADRB3 P13945 1/20 0.49
ADRA2B P18089 1/20 0.49
ADRA2C P18825 1/20 0.49
DRD1 P21728 1/20 0.49
DRD5 P21918 1/20 0.49
SLC6A2 P23975 1/20 0.49
AGTR1 P30556 1/20 0.49
NTSR1 P30989 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL22638730 0.93 HTR2C (0.64) HTR2CP2RY14TMEM97JAK3HTR3A
SCHEMBL16660400 0.91 HTR2C (0.79) HTR2CP2RY14TMEM97HTR3A
SCHEMBL17938547 0.91 HTR2C (0.79) HTR2CP2RY14TMEM97HTR3A
SCHEMBL1811550 0.91 HTR2C (0.79) HTR2CP2RY14TMEM97HTR3A
Hydrochloric Acid SCHEMBL4573167 0.89 HTR2C (0.80) HTR2CP2RY14TMEM97HTR3A
SCHEMBL1988878 0.85 JAK3 (0.71) JAK3
Hydrochloric Acid SCHEMBL1991837 0.84 JAK3 (0.70) HTR2CJAK3
Trifluoroacetic Acid SCHEMBL2303613 0.83 HTR2C (0.78) HTR2CP2RY14TMEM97PDE2APDE5A
Oxalic Acid SCHEMBL3552533 0.83 JAK3 (0.56) JAK3HTR3A
SCHEMBL29537253 0.83

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7666888-B2 Substituted azole aromatic heterocycles as inhibitors of 11β-HSD-1 AMGEN INC. (US) 2010-02-23 US disclosed
EP-2051977-A2 SUBSTITUTED AZOLE AROMATIC HETEROCYCLES AS INHIBITORS OF LLbeta-HSD-1 Amgen Inc. (US) 2009-04-29 EP disclosed
WO-2008011453-A2 SUBSTITUTED AZOLE AROMATIC HETEROCYCLES AS INHIBITORS OF LLβ-HSD-1 AMGEN INC. (US) 2008-01-24 WO disclosed
US-20080021022-A1 SUBSTITUTED AZOLE AROMATIC HETEROCYCLES AS INHIBITORS OF 11BETA-HSD-1 AMGEN INC. 2008-01-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080021022-A1 SUBSTITUTED AZOLE AROMATIC HETEROCYCLES AS INHIBITORS OF 11BETA-HSD-1 HSD17B1, HSD11B1, HSD17B11 SLC6A4 1532/4885HTR2C 1165/4885P2RY14 4318/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.